Bausch + Lomb Co. (NYSE:BLCO) Receives Average Recommendation of "Hold" from Brokerages

Bausch + Lomb Co. (NYSE:BLCO - Get Free Report) has been given a consensus rating of "Hold" by the thirteen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $20.58.

Several equities analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $23.00 price objective on shares of Bausch + Lomb in a research note on Thursday, December 12th. Royal Bank of Canada raised their price target on shares of Bausch + Lomb from $20.00 to $23.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 22nd. Wells Fargo & Company lifted their price target on shares of Bausch + Lomb from $23.00 to $26.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. Morgan Stanley cut shares of Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 target price on the stock. in a report on Monday, December 2nd. Finally, Stifel Nicolaus upped their target price on Bausch + Lomb from $16.00 to $19.00 and gave the company a "hold" rating in a report on Monday, September 23rd.

Institutional Investors Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new stake in Bausch + Lomb in the second quarter worth approximately $173,000. Polar Asset Management Partners Inc. bought a new stake in shares of Bausch + Lomb in the 3rd quarter worth $289,000. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bausch + Lomb in the third quarter valued at $289,000. Verition Fund Management LLC bought a new position in Bausch + Lomb during the third quarter valued at about $302,000. Finally, XTX Topco Ltd acquired a new position in Bausch + Lomb during the third quarter worth about $309,000. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Stock Down 1.4 %

BLCO stock traded down $0.26 during mid-day trading on Friday, hitting $17.74. 289,964 shares of the company were exchanged, compared to its average volume of 316,032. The company has a market capitalization of $6.25 billion, a PE ratio of -16.90, a price-to-earnings-growth ratio of 1.74 and a beta of 0.43. The firm has a fifty day simple moving average of $19.28 and a 200 day simple moving average of $17.84. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Bausch + Lomb has a twelve month low of $13.16 and a twelve month high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the firm earned $0.22 earnings per share. The company's revenue for the quarter was up 18.8% compared to the same quarter last year. On average, research analysts forecast that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.